Tirzepatide (Zepbound) came out on top against semaglutide (Wegovy) for treating obesity in the head-to-head SURMOUNT-5 trial.

Veru VERU is gearing up to announce its quarterly earnings on Thursday, 2025-05-08. Here's a quick overview of what investors should know before the release. Analysts are estimating that Veru will ...

Novo Nordisk said first-quarter sales of Wegovy were 17.36 billion Danish crowns ($2.64 billion), declining 13% from the previous quarter, and below the 18.7 billion crowns expected by analysts.

Caremark negotiated an undisclosed lower net price for Wegovy over Zepbound on its standard formularies, offering savings on Novo Nordisk's drug to clients that opt into those plans. But ...

Q1 Wegovy sales rose 85% to DKK 17.36 billion; Ozempic up 18% to DKK 32.72 billion. Novo Nordisk's Q1 sales hit $10.89 billion, missing the $11.64 billion consensus estimate. Get 5 ‘Hidden Gem ...

Shares of Novo Nordisk jumped nearly 7% on Wednesday after it said sales of its blockbuster Wegovy weight loss drug were seen improving in the second half of the year as the availability of ...